Vaxcyte, Inc.(PCVX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
PCVX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Vaxcyte, Inc. (PCVX), a Healthcare sector company. PCVX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Vaxcyte, Inc. reports net income of $-284.3M, free cash flow of $-236.8M. Top institutional holders of PCVX by reported 13-F value include FMR, Jupiter Topco, T. Rowe Price Investment Management, based on the most recent SEC filings. PCVX trades on the Nasdaq exchange and files with the SEC under CIK 1649094. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PCVX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vaxcyte, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-284.3M
Free Cash Flow
Q2 2026
$-236.8M
ROIC
Q2 2026
-43.9%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-65.2% YoYOperating Income
-62.2% YoYEPS (Diluted)
-48.2% YoYTotal Assets
-14.5% YoYOp. Cash Flow
-44.8% YoYFree Cash Flow
-40.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-766.6M -65.2% | $-463.9M -15.3% | $-402.3M -80.0% | $-223.5M -123.3% | $-100.1M -12.2% | $-89.2M |
| Operating Income | $-923.7M -62.2% | $-569.5M -21.7% | $-468.0M -101.5% | $-232.3M -124.0% | $-103.7M -15.7% | $-89.6M |
| EPS (Diluted) | $-5.63 -48.2% | $-3.80 +8.2% | $-4.14 -20.3% | $-3.44 -78.2% | $-1.93 +36.1% | $-3.02 |
| Total Assets | $3.00B -14.5% | $3.51B +149.4% | $1.41B +39.9% | $1.01B +210.2% | $324.3M -17.4% | $392.8M |
| Operating Cash Flow | $-655.6M -44.8% | $-452.6M -52.5% | $-296.8M -74.0% | $-170.6M -40.5% | $-121.4M -160.3% | $-46.6M |
| Free Cash Flow | $-669.3M -40.9% | $-475.1M -51.8% | $-312.9M -77.3% | $-176.4M -37.9% | $-127.9M -167.8% | $-47.8M |
Get alerted when PCVX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Vaxcyte, Inc. including:
Top Institutional Holders of PCVX
FMR LLC
$1.2B20,852,907 shJupiter Topco LLC
$1.0B17,965,847 shT. Rowe Price Investment Management, Inc.
$709.6M12,207,450 shBlackRock, Inc.
$701.5M12,068,129 shRA CAPITAL MANAGEMENT, L.P.
$667.0M11,474,599 shWELLINGTON MANAGEMENT GROUP LLP
$407.0M7,001,565 shVANGUARD PORTFOLIO MANAGEMENT LLC
$383.3M6,593,551 shVANGUARD CAPITAL MANAGEMENT LLC
$369.0M6,348,679 shSTATE STREET CORP
$311.1M5,351,698 shDeep Track Capital, LP
$250.0M4,300,000 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $1.2B | 20,852,907 |
| Jupiter Topco LLC | $1.0B | 17,965,847 |
| T. Rowe Price Investment Management, Inc. | $709.6M | 12,207,450 |
| BlackRock, Inc. | $701.5M | 12,068,129 |
| RA CAPITAL MANAGEMENT, L.P. | $667.0M | 11,474,599 |
| WELLINGTON MANAGEMENT GROUP LLP | $407.0M | 7,001,565 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $383.3M | 6,593,551 |
| VANGUARD CAPITAL MANAGEMENT LLC | $369.0M | 6,348,679 |
| STATE STREET CORP | $311.1M | 5,351,698 |
| Deep Track Capital, LP | $250.0M | 4,300,000 |
More Healthcare Companies
View all Healthcare →Put PCVX on your watchlist
Track score changes the day Vaxcyte, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PCVX a good stock to buy?
13F Pro's AI-powered analysis of Vaxcyte, Inc. (PCVX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PCVX are available on the PCVX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PCVX is classified as a mid company.
Which hedge funds own PCVX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PCVX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Vaxcyte, Inc.'s investment landscape.